Bladder Cancer Treatment Impact: Barriers to Quality of Life in Patients

A global survey highlights the profound bladder cancer treatment impact on patients with non-muscle-invasive bladder cancer, with more than 90 percent of those undergoing radical cystectomy or BCG therapy reporting negative physical, emotional, and mental health effects.

Life-Altering Effects

Patients frequently missed key life events, including more than one-third who avoided socializing or public activities, while three-quarters of BCG-treated individuals described managing symptoms as humiliating. The bladder cancer treatment impact extended to daily routines, body image, and self-esteem for over nine in ten radical-cystectomy patients.

The survey data underscore profound daily-life interference, as 94 percent of patients missed at least one important moment due to therapy. More than one-third of patients prioritize limiting life disruption when selecting treatments, a view shared by nearly half of surveyed urologists, highlighting how current regimens extend burdens well beyond clinical settings.

Survey Insights

The research was executed online by The Harris Poll between November 25 and December 29, 2025, on behalf of Johnson & Johnson in partnership with the International Bladder Cancer Group, the World Bladder Cancer Patient Coalition, and the Bladder Cancer Advocacy Network. Eligible participants included adults diagnosed with NMIBC who maintain a urologist as primary provider, alongside urologists treating at least one NMIBC case monthly, drawn equally from the United States, Mexico, Brazil, Japan, Germany, and France.

Broader Implications

Findings from the survey carry direct relevance for Health Economics and Outcomes Research evaluations, as the documented effects on patient functioning and emotional well-being suggest opportunities to incorporate broader quality-of-life metrics into value assessments. Urologists’ expressed regret over radical cystectomy recommendations in nearly 40 percent of cases points to potential shifts in market access strategies that favor therapies demonstrating measurable gains in daily participation.